Replies to post #181345 on Biotech Values

[DewDiligence]

FLML -40% on new competition:

http://finance.yahoo.com/news/flamel-technologies-shareholders-neostigmine-methylsulfate-181500894.html

Flamel Technologies today learned the U.S. Food and Drug Administration has approved Fresenius Kabi's New Drug Application (NDA) for neostigmine methylsulfate, a drug which Flamel currently markets as Bloxiverz.

The Company is in discussions with regulatory and legal counsel to evaluate options that will minimize the potential competitive impact of Fresenius Kabi's NDA approval. An update will be provided to shareholders as more information becomes available.

My earlier post that said the FLML sell-off was based on a court ruling was incorrect.